A5012679459- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Eosinophilic Disorders and Syndromes
- Lung Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Inhalation and Respiratory Drug Delivery
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Long-Term Effects of COVID-19
- Occupational exposure and asthma
- Pneumonia and Respiratory Infections
- Lung Cancer Treatments and Mutations
- Pulmonary Hypertension Research and Treatments
- Systemic Sclerosis and Related Diseases
- COVID-19 Clinical Research Studies
- Immunodeficiency and Autoimmune Disorders
- Head and Neck Cancer Studies
- Fungal Plant Pathogen Control
- Renal Diseases and Glomerulopathies
- COVID-19 and healthcare impacts
- Ultrasound in Clinical Applications
- COVID-19 diagnosis using AI
- Blood disorders and treatments
- Pharmacovigilance and Adverse Drug Reactions
Università Cattolica del Sacro Cuore
2017-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
Agostino Gemelli University Polyclinic
2019-2023
St. Paul's Hospital
2021
Hospital Sant Joan de Déu Barcelona
2018
Vall d'Hebron Hospital Universitari
2012
Progressive fibrosing interstitial lung disease (PF-ILD) is characterised by progressive physiological, symptomatic and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain.Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015 2020. was defined as a relative forced vital capacity (FVC) decline ≥10%, death, transplantation or any two of: FVC ≥5% <10%, worsening respiratory symptoms fibrosis on computed tomography...
Introduction Following the INPULSIS and ASCEND studies, leading to first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents a targeted effective better tolerated therapy able improve natural history of disease.
In patients with pneumonia from novel coronavirus SARS-CoV-2, the appearance of interstitial changes on chest high-resolution computed tomography (HRCT) suggests possible development fibrosis,1 which has been confirmed in histological samples.2 The persistence COVID-related lung abnormalities following hospitalization estimated up to two third surviving patients3, 4 and can be responsible for residual respiratory impairment.5, 6 As such, there is ground believe that a combination...
Although crackles on chest auscultation represent a fundamental component of the diagnostic suspect for fibrotic interstitial lung disease (ILD), their reliability has not been properly studied. We assessed agreement among respiratory physicians presence and changes over time audible collected in prospective longitudinal cohort patients with ILD.
<h3>Background</h3> The current complexity of pharmacotherapy in patients with orthopaedic infections increases the risk drug-drug interactions (DDI). <h3>Purpose</h3> aim this study is to identify potential DDI (severe/moderate) and its clinical relevance admitted infectious diseases unit (IDU) a tertiary trauma hospital. <h3>Materials methods</h3> Prospective observational performed from January 2011 April (100 days) IDU for at least 7 days. following variables were recorded each patient...
<h3>Background</h3> Approved therapeutic indications for human normal immunoglobulin (HNIg) in the paediatric population are: primary immunodeficiency syndromes, hypogammaglobulinaemia post-stem cell transplantation, AIDS with recurrent infections and immune thrombocytopenia (ITP), among others. Apart from those, HNIg are also used off-label many clinical indications. <h3>Purpose</h3> To describe use of haematological oncologic patients a teaching hospital. <h3>Material methods</h3> We...